Bio-Rad Laboratories, Inc. announced it has received the Frost & Sullivan 2012 North American Market Penetration Leadership Award in Quantitative and Digital PCR Instrumentation. This annual award honors the company that has demonstrated excellence by growing market share at the fastest rate in its industry, as measured by revenues or units sold.
Frost & Sullivan, a global growth consulting company, cited findings from its best practices research that show Bio-Rad has built a solid reputation in amplification technologies. According to Frost & Sullivan’s research, Bio-Rad continually releases innovative products to earn customer loyalty and gain market share, with particularly strong market positions in both the real-time PCR (qPCR) and digital (dPCR) instrumentation markets.
“Bio-Rad clearly exhibits some of the key traits shared by the most successful companies: the ability to locate and solve unmet needs in the markets they serve and a dedication to continuous R&D,” said Christi Bird, life sciences senior industry analyst at Frost & Sullivan. “Bio-Rad’s commitment to innovation, coupled with its keen focus on other qualities valued most by its customers, has resulted in a strong and growing market position that makes the company an ideal recipient of this year’s Frost & Sullivan Market Penetration Leadership Award.”
“We are honored to receive recognition of our leadership in the real-time and digital PCR markets,” said Rachel Scott, amplification instruments business unit marketing manager at Bio-Rad. “The Frost & Sullivan award is a reflection of how we strive to develop innovative new solutions that align with the needs of the research community in terms of both technology and pricing.”
Frost & Sullivan expects Bio-Rad to continue its market share gains in qPCR with several instruments launched in 2011, including the CFX96 Touch™ and CFX Connect™ real-time PCR detection systems.
In the dPCR market, Frost & Sullivan believes the QX100™ Droplet Digital™ PCR system holds the greatest promise of all dPCR instruments currently on the market, due to its simplicity, performance, and affordability. The QX100 system has already received significant attention from pharmaceutical companies and cancer research laboratories, leading Frost & Sullivan to believe that the instrument will be the early market leader in the expanding dPCR market.
“Bio-Rad has also seen a great deal of interest from the growing molecular diagnostic market,” said James Lee, Droplet Digital PCR commercialization marketing manager at Bio-Rad. “We plan to participate in this market in the near future using our ddPCR™ technology.”
Bio-Rad was honored with this recognition at Frost & Sullivan’s 2012 Excellence in Best Practices Awards Banquet on November 8 in San Antonio, Texas. The event highlighted companies, strategies, processes, and executives that have achieved world-class performance within their industries.
For more information about Bio-Rad’s PCR products, visit http://bit.ly/PCR_Products.